Concurrent chemotherapy and first‐generation epidermal growth factor receptor (EGFR)‐tyrosine kinase inhibitors (TKIs) with or without an antiangiogenic agent as first‐line treatment in advanced lung adenocarcinoma harboring an EGFR mutation

Concurrent chemotherapy and first‐generation epidermal growth factor receptor (EGFR)‐tyrosine kinase inhibitors (TKIs) with or without an antiangiogenic agent as first‐line treatment in advanced lung adenocarcinoma harboring an EGFR mutation

Abstract Background Previous studies have demonstrated the combination of epidermal growth factor receptor (EGFR)‐tyrosine kinase inhibitors (TKIs) and other antitumor agents may delay drug resistance. In this study, we retrospectively reviewed the efficacy and safety of first‐line concurrent EGFR‐T...

Full description

Bibliographic Details
Main Authors: Ziyi Xu, Xuezhi Hao, Lin Lin, Junling Li, Puyuan Xing
Format: Article
Language:English
Published: Wiley 2021-08-01
Series:Thoracic Cancer
Subjects:
advanced lung adenocarcinoma
concurrent therapy
epidermal growth factor receptor (EGFR)‐tyrosine kinase inhibitor (TKI)
first‐line therapy
platinum‐based doublet chemotherapy
Online Access:https://doi.org/10.1111/1759-7714.14057

Internet

https://doi.org/10.1111/1759-7714.14057

Similar Items